MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example Observation: PIK3R1 Therapeutische Implikation

English

Profile: MII PR MTB Therapeutische Implikation version: 2027.0.0-ballot.1

MII EX MTB Empfehlung Evidenzgraduierung: Preclinical data (in vitro, in vivo models or functional genomics studies) demonstrate that the biomarker predicts response to a specific drug treatment, supported by scientific rationale.

status: Final

category: Laboratory, Genetics

code: Therapeutic Implication

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

derivedFrom: Observation Genetic variant assessment

component

code: Conclusion Text

value: Ausweislich praeklinischer Daten liegt ein Ansprechen auf MEK-Inhibition nahe (PMID: 31209687, EL m3).

component

code: Medication assessed [ID]

value: Mitogen-aktivierte Proteinkinase (MEK)-Inhibitoren